Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)

Detalhes bibliográficos
Autor(a) principal: LI,Zhiying
Data de Publicação: 2022
Outros Autores: LI,Junjiao, LI,Minqiang, CAI,Ansheng, LIU,Hong, MIAO,Guoying, SHAN,Tieying, MA,Jinghong
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Food Science and Technology (Campinas)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612022000101283
Resumo: Abstract Matrix metalloproteinases have been proven to be the target of Alzheimer’s disease (AD) drugs. In this study, by monitoring the effects of different doses of Astragalus P.E on the serum level of matrix metalloproteinase (MMP) in patients with Alzheimer's disease. A cell model was established to explore the the protective effect and therapeutic basis of Astragalus P.E targeting matrix metalloproteinases on AD synapses. Using MTT to detect the effect of different doses of Astragalus P.E on the content of matrix metalloproteinase protein in the serum of patients with Alzheimer's disease; selecting the appropriate concentration and time as the modeling conditions of AD cells, transfecting PC12 cells by constructing the MMP promoter double luciferase reporter gene and Astragalus P.E was used as a treatment factor to observe the effect of Astragalus P.E on the transcription activity of MMP promoter. Observe the protective effect of Astragalus P.E on AD cell model and the effect on MMP expression. The AD cell model was transfected with MMP-siRNA to observe whether MMP is the key link in the effect of Astragalus P.E. 10 μM Astragalus P.E was used to induce PC12 cells for 24 h as the early AD cell model. Astragalus P.E can effectively inhibit the increase of transcription activity of MMP promoter induced by Astragalus P.E. Astragalus P.E can reduce the expression of MMP in PC12 cells induced by Astragalus P.E. At the same time, after transfection with MMP-siRNA plasmid, Astragalus P.E can significantly change the expression of MMP in PC12 cells induced by Astragalus P.E. Astragalus P.E targeting MMP has a protective effect on AD synapse damage, and it is a key link for the Astragalus P.E to exert medicinal effects.
id SBCTA-1_468ddd8258939cffd3d74415a7ab5d74
oai_identifier_str oai:scielo:S0101-20612022000101283
network_acronym_str SBCTA-1
network_name_str Food Science and Technology (Campinas)
repository_id_str
spelling Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)Alzheimer's diseaseserum matrix metalloproteinase proteinAstragalus P.Etherapeutic basisAbstract Matrix metalloproteinases have been proven to be the target of Alzheimer’s disease (AD) drugs. In this study, by monitoring the effects of different doses of Astragalus P.E on the serum level of matrix metalloproteinase (MMP) in patients with Alzheimer's disease. A cell model was established to explore the the protective effect and therapeutic basis of Astragalus P.E targeting matrix metalloproteinases on AD synapses. Using MTT to detect the effect of different doses of Astragalus P.E on the content of matrix metalloproteinase protein in the serum of patients with Alzheimer's disease; selecting the appropriate concentration and time as the modeling conditions of AD cells, transfecting PC12 cells by constructing the MMP promoter double luciferase reporter gene and Astragalus P.E was used as a treatment factor to observe the effect of Astragalus P.E on the transcription activity of MMP promoter. Observe the protective effect of Astragalus P.E on AD cell model and the effect on MMP expression. The AD cell model was transfected with MMP-siRNA to observe whether MMP is the key link in the effect of Astragalus P.E. 10 μM Astragalus P.E was used to induce PC12 cells for 24 h as the early AD cell model. Astragalus P.E can effectively inhibit the increase of transcription activity of MMP promoter induced by Astragalus P.E. Astragalus P.E can reduce the expression of MMP in PC12 cells induced by Astragalus P.E. At the same time, after transfection with MMP-siRNA plasmid, Astragalus P.E can significantly change the expression of MMP in PC12 cells induced by Astragalus P.E. Astragalus P.E targeting MMP has a protective effect on AD synapse damage, and it is a key link for the Astragalus P.E to exert medicinal effects.Sociedade Brasileira de Ciência e Tecnologia de Alimentos2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612022000101283Food Science and Technology v.42 2022reponame:Food Science and Technology (Campinas)instname:Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)instacron:SBCTA10.1590/fst.48622info:eu-repo/semantics/openAccessLI,ZhiyingLI,JunjiaoLI,MinqiangCAI,AnshengLIU,HongMIAO,GuoyingSHAN,TieyingMA,Jinghongeng2022-08-16T00:00:00Zoai:scielo:S0101-20612022000101283Revistahttp://www.scielo.br/ctaONGhttps://old.scielo.br/oai/scielo-oai.php||revista@sbcta.org.br1678-457X0101-2061opendoar:2022-08-16T00:00Food Science and Technology (Campinas) - Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)false
dc.title.none.fl_str_mv Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)
title Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)
spellingShingle Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)
LI,Zhiying
Alzheimer's disease
serum matrix metalloproteinase protein
Astragalus P.E
therapeutic basis
title_short Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)
title_full Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)
title_fullStr Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)
title_full_unstemmed Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)
title_sort Research of therapeutic basis of Astragalus P.E intervention based on the content of matrix metalloproteinase (MMP) protein in the serum of patients with Alzheimer's disease (AD)
author LI,Zhiying
author_facet LI,Zhiying
LI,Junjiao
LI,Minqiang
CAI,Ansheng
LIU,Hong
MIAO,Guoying
SHAN,Tieying
MA,Jinghong
author_role author
author2 LI,Junjiao
LI,Minqiang
CAI,Ansheng
LIU,Hong
MIAO,Guoying
SHAN,Tieying
MA,Jinghong
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv LI,Zhiying
LI,Junjiao
LI,Minqiang
CAI,Ansheng
LIU,Hong
MIAO,Guoying
SHAN,Tieying
MA,Jinghong
dc.subject.por.fl_str_mv Alzheimer's disease
serum matrix metalloproteinase protein
Astragalus P.E
therapeutic basis
topic Alzheimer's disease
serum matrix metalloproteinase protein
Astragalus P.E
therapeutic basis
description Abstract Matrix metalloproteinases have been proven to be the target of Alzheimer’s disease (AD) drugs. In this study, by monitoring the effects of different doses of Astragalus P.E on the serum level of matrix metalloproteinase (MMP) in patients with Alzheimer's disease. A cell model was established to explore the the protective effect and therapeutic basis of Astragalus P.E targeting matrix metalloproteinases on AD synapses. Using MTT to detect the effect of different doses of Astragalus P.E on the content of matrix metalloproteinase protein in the serum of patients with Alzheimer's disease; selecting the appropriate concentration and time as the modeling conditions of AD cells, transfecting PC12 cells by constructing the MMP promoter double luciferase reporter gene and Astragalus P.E was used as a treatment factor to observe the effect of Astragalus P.E on the transcription activity of MMP promoter. Observe the protective effect of Astragalus P.E on AD cell model and the effect on MMP expression. The AD cell model was transfected with MMP-siRNA to observe whether MMP is the key link in the effect of Astragalus P.E. 10 μM Astragalus P.E was used to induce PC12 cells for 24 h as the early AD cell model. Astragalus P.E can effectively inhibit the increase of transcription activity of MMP promoter induced by Astragalus P.E. Astragalus P.E can reduce the expression of MMP in PC12 cells induced by Astragalus P.E. At the same time, after transfection with MMP-siRNA plasmid, Astragalus P.E can significantly change the expression of MMP in PC12 cells induced by Astragalus P.E. Astragalus P.E targeting MMP has a protective effect on AD synapse damage, and it is a key link for the Astragalus P.E to exert medicinal effects.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612022000101283
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612022000101283
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/fst.48622
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Ciência e Tecnologia de Alimentos
publisher.none.fl_str_mv Sociedade Brasileira de Ciência e Tecnologia de Alimentos
dc.source.none.fl_str_mv Food Science and Technology v.42 2022
reponame:Food Science and Technology (Campinas)
instname:Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)
instacron:SBCTA
instname_str Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)
instacron_str SBCTA
institution SBCTA
reponame_str Food Science and Technology (Campinas)
collection Food Science and Technology (Campinas)
repository.name.fl_str_mv Food Science and Technology (Campinas) - Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)
repository.mail.fl_str_mv ||revista@sbcta.org.br
_version_ 1752126335076007936